HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $17 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $17 price target.
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's morning session saw 84 companies set new 52-week lows.
BMO Capital Downgrades Precision BioSciences to Market Perform, Lowers Price Target to $4
BMO Capital analyst Kostas Biliouris downgrades Precision BioSciences (NASDAQ:DTIL) from Outperform to Market Perform and lowers the price target from $7 to $4.
Earnings Scheduled For March 9, 2023
Companies Reporting Before The Bell
• Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.
Precision BioSciences Receives Favorable Type C Feedback From FDA On Company’s Chemistry, Manufacturing And Controls Strategies For Late-Stage Development Of Azercabtagene Zapreleucel, Its Lead Allogeneic CAR T Clinical Candidate
- FDA feedback signals the Company's CMC plans shared are in alignment with Agency requirements and expectations
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 325 companies set new 52-week lows.
Goldman Sachs Maintains Neutral on Precision BioSciences, Lowers Price Target to $1
Goldman Sachs analyst Salveen Richter maintains Precision BioSciences (NASDAQ:DTIL) with a Neutral and lowers the price target from $2 to $1.
HC Wainwright & Co. Maintains Buy on Precision BioSciences, Lowers Price Target to $17
HC Wainwright & Co. analyst Patrick Trucchio maintains Precision BioSciences (NASDAQ:DTIL) with a Buy and lowers the price target from $20 to $17.